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Abstract
Genetic epidemiology studies often adjust for numerous potential confounders, yet the influences
of confounder misclassification and selection bias are rarely considered. We used simulated data to
evaluate the effect of confounder misclassification and selection bias in a case-control study of
incident myocardial infarction. We show that putative confounders traditionally included in genetic
association studies do not alter effect estimates, even when excessive levels of misclassification are
incorporated. Conversely, selection bias resulting from covariates affected by the single-nucleotide
polymorphism of interest can bias effect estimates upward or downward. These results support
careful consideration of how well a study population represents the target population because
selection bias may result even when associations are modest.
Background
Genetic epidemiology studies often adjust for numerous
covariates when estimating associations between genetic
variants and an outcome of interest [1-3]. However,
several authors have questioned whether acquired risk
factors can confound genetic associations [4-6]. Others
have suggested that confounders only influence genetic
associations through selection bias [7,8]. We therefore
initially investigated whether acquired risk factors con-
founded the association between two simulated causal
single-nucleotide polymorphisms (SNPs) and the odds
of myocardial infarction (MI) using the Genetic Analysis
Workshop 16 simulated data. This platform facilitated
an evaluation of non-differential and differential mis-
classification in potential confounders, as well as
selection bias.
Methods
Study population and sources of data
The Framingham Heart Study simulated dataset provided
included 6,476 Caucasians from 1,129 pedigrees. Indivi-
duals were genotyped using a 50 k gene-focused panel and
a 500 k Human Mapping Array Set provided by Affymetrix.
We selected unrelated participants from the cohort and
offspring populations (n = 1,741) and examined two SNPs
using a dominant genetic model: rs12565497, simulated
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association with MI (Scenario 1, the investigation of
differential and non-differential misclassification), and
rs1466535, simulated association with low-density lipo-
protein (LDL) concentrations (Scenario 2, the investigation
of selection bias). MI was defined as any MI over the
three simulated study exams. Baseline LDL concentrations
dichotomized at 160 mg/dl were used to examine the effect
of selection bias. Baseline smoking history and medication
use (Rx) were used to evaluate misclassification.
Statistical methods
Confounders of the association between the SNP and MI
were identified using two methods. First, we employed a
directed acyclic graph (DAG), which allowed us to apply a
simple set of rules to graphically encode relationships
between study variables [9]. DAGs are particularly infor-
mative because they make untested assumptions between
variables explicit so that their implications can be studied
further. Second, we evaluated potential confounders using
established criteria that required an association between
the potential confounder and the exposure (i.e., the SNP)
among those without MI as well as an association
between the potential confounder and MI within the
whole population [10]. Statistical tests were not used to
identify confounding because they only evaluate the
confounder-outcome association.
Non-differential misclassification in confounder mea-
surement (i.e., confounder misclassification unrelated to
disease) was examined several ways. First, we evaluated
smoking history and Rx separately by including each
variable in the initial model that only included
rs12565497 and randomly changing the true covariate
values in 0.5-25% of the population. We also evaluated
the potential for joint non-differential misclassification
by including both smoking and Rx in the initial model
and independently altering 5-25% of the true covariate
values for each putative confounder. To evaluate the
effect of misclassification related to the true confounder
values, we also considered models that fixed the
probability of smoking misclassification for non-smo-
kers and Rx (regardless of status) at 2% and varied the
misclassification probability for smokers from 2-30%.
We did not vary Rx misclassification by usage because we
did not believe that the misreporting proportion would
vary by usage status, unlike smoking. The low prevalence
of usage (3.3%) also limited our analytic options.
Differential misclassification in confounder measure-
ment (i.e., confounder misclassification related to dis-
ease) was also evaluated for each potential confounder
separately and jointly. For example, differential mis-
classification in smoking history was examined by fixing
the misclassification proportion for participants who did
not smoke and did not develop a MI at 0.98. The
misclassification proportion for persons who smoked
and had a MI was varied from 0.70 to 0.85. Non-smokers
with a MI or smokers without a MI were assigned
intermediate probabilities of misclassification.
Selection bias (e.g., inappropriate control selection,
healthy-worker bias, or non-response bias [11]) was
investigated using rs1466535, simulated to influence
LDL concentrations. First we estimated the rs1466535-
MI relationship. We then introduced selection bias by
randomly removing 5-60% of the following four
populations: high LDL, low LDL, smokers, and non-
smokers. We also evaluated the effect of selection bias
related to smoking and LDL jointly by fixing the
participation proportions for the low LDL population
at 1.0 and the non-smoking population with high LDL
at 0.8. The participation proportion for persons who
smoked and had high LDL was then varied from 0.4-0.7.
All analyses were performed unblinded to the answers
using logistic regression, 500 iterations on the first
simulated dataset in SAS 9 (Cary, NC).
Results
The minor allele frequencies of rs12565497 and rs1466535
are 0.30 and 0.32, respectively. Both SNPs are in Hardy-
Weinberg equilibrium. The estimated prevalences of MI,
smoking, high LDL, and Rx are 26.1%, 24.3%, 67%, and
3.3%, respectively.
Table 1 and Figure 1 present the relationships between the
genetic variants, putative confounders, and MI from
Scenarios A (confounder misclassification) and B (selection
bias). The Scenario A DAG demonstrates that neither
smoking nor Rx confounds the association between
Table 1: Relationship between genetic variants, putative con-
founders, and MI used to examine misclassification (Scenario A)
and selection bias (Scenario B)
Exposure Outcome Population Estimate (95% CI)
Scenario A
rs12565497 Smoking MI = 0 0.95 (0.73, 1.25)
Smoking MI Total population 2.08 (1.48, 2.94)
rs12565497 Rx MI = 0 0.60 (0.25, 1.40)
Rx MI Total population 2.62 (1.18, 5.80)
Scenario B
rs1466535 Smoking MI = 0 1.15 (0.88, 1.51)
Smoking MI rs1466535 AAa 2.03 (1.60, 2.57)
Smoking LDLb Total population 1.31 (1.03, 1.66)
rs1466535 LDLb Total population 0.81 (0.66, 0.99)
rs1466535 Smoking Total population 1.14 (0.91, 1.42)
rs1466535 MI Total population 0.80 (0.64, 1.00)
aReferent group.
bLDL dichotomized at 160 mg/dl.
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rs12555497 and MI because neither is associated with the
SNP. This is supported by the odds ratios (OR) for
rs12565497-smoking (OR = 0.95; 95% CI = 0.73, 1.25)
and rs12565497-Rx (OR = 0.60; 95% CI = 0.25, 1.40). The
estimates of the SNP-MI association adjusted for Rx (OR =
1.46; 95% CI = 1.17, 1.81), smoking (OR = 1.47; 95% CI =
1.19, 1.83), and Rx and smoking together (OR = 1.47; 95%
CI = 1.18, 1.83) are also very similar to the unadjusted
estimate (OR = 1.47; 95% CI = 1.18, 1.82), further
suggesting that neither confounds the rs12555497-MI
association (results not shown).
Due to space restrictions, only selected results of iterative
analyses evaluating the effect of non-differential mis-
classification by jointly including smoking status and Rx
are reported in Table 2. Results show that the estimate of
the “truth” was included in the range generated by the
500 iterations, and that there was no bias in the SNP-MI
estimate or standard error. We note that as the smoking
misclassification proportion increases for smokers, the
percent of estimates biased toward the null (defined as
the proportion of estimates that were reduced in
magnitude) increased.
As above, only selected results from differential mis-
classification analyses in which the probability of
misreporting depended on both smoking status and
the outcome are reported in Table 3. Iterative analyses
suggested that differential misclassification does not bias
the estimate of the SNP-MI association. In contrast
to non-differential results, however, we note that as
misclassification increases, the percent of estimates
biased toward the null decreases. Results of other non-
differential and differential misclassification analyses
were consistent with these conclusions.
The Scenario B DAG (Figure 1) suggests that smoking and
LDL do not confound the rs1466535-MI association (not
shown). While rs1466535 is associated with LDL (Table 1),
LDL is on the causal pathway; adjusting for it could bias
the rs1466535-MI association or induce confounding [12].
The DAG also illustrates the potential for selection bias
Table 2: Effect of non-differential misclassification of smoking status and Rx on the rs12565497-MI association
% Misclassified Average bias
Smokers Non-smokers Rx Estimate SE Range % Biased toward null
“Truth” (0% misclassification) 0.389a 0.111a - -
2 2 2 0.003 0.001 0.377-0.407 25.8
5 2 2 0.003 0.001 0.371-0.413 27.2
10 2 2 0.002 0.001 0.372-0.411 34.8
20 2 2 0.002 0.001 0.361-0.417 42.4
30 2 2 0.001 0.000 0.363-0.421 45.0
aDenotes “true” estimate and standard error.
Table 3: Effect of differential misclassification of smoking status on the rs12565497-MI association
% Misclassified Average bias
MI
smokers
MI
non-smokers
No MI
smokers
No MI
non-smokers
Estimate SE Range % Biased toward null
“Truth” (Assumes 0% misclassification) 0.3889a 0.1111a - -
15 5 10 2 -0.002 0.000 0.367-0.408 65.0
20 10 15 2 -0.001 0.000 0.360-0.421 56.6
25 15 20 2 -0.001 0.001 0.349-0.447 51.4
30 20 25 2 0.000 0.002 0.332-0.451 51.2
aDenotes “true” estimate and standard error.
Figure 1
DAGs detailing potential confounding (A) and
selection bias (B) in a simulated case-control study
of MI.
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related to LDL levels. For instance, if LDL levels influence
participation, a non-random sample of the target popula-
tion could bias estimates of the rs1466535-MI association.
Results in Table 4 show that decreasing the participation
proportion for the high LDL or non-smoking populations
negatively biases the rs1466535-MI association; this bias is
larger for high LDL. Conversely, positive bias is observed
when decreasing either the participation proportion for the
low LDL or smoking populations. Results of other selection
bias analyses were consistent with these conclusions.
Discussion
In this paper, we evaluated how misclassification and
selection bias affected putative confounders in genetic
association studies. We demonstrated that putative
confounders did not alter effect estimates. Conversely,
selection bias resulting from covariates affected by the
SNP of interest could bias effect estimates upward or
downward, the degree of bias and its direction depend-
ing on underlying relationships between the SNP,
intermediate variable, and the outcome of interest.
A true confounder is defined as a variable that affects both
the exposure and the outcome [10]. In this simulation study
we used both smoking status and Rx as putative confoun-
ders. These confounders did not meet our criteria of “true”
confounders in that there was no association between the
confounder and the SNP among those that did not have an
MI, although there was an association between the
confounder and MI (see Table 1). Similarly, smoking and
Rx did not fit conventional criteria as established by the
DAG (Scenario A, Figure 1). Nonetheless, such covariates are
often included in statistical models; authors state that they
are eliminating excess variation, following standards set by
the literature, or provide other rationales. Given that the
majority of variables are measured with some degree of
error, which may lead to misclassification, we hypothesized
that explicitly introducing misclassification would alter the
SNP-MI association. However, we did not find this, even
when misclassifying substantial proportions of the popula-
tion. Other covariates may function as true confounders in
this association, among them race or study center, and
might introduce bias ifmeasuredwith systematic error. Such
variables were not available in these data.
Ideal referent groups in case-control studies are popula-
tions that approximate the population from which the
cases arose (i.e., the target population) [13,14]. As such,
the relevant comparison to assess the adequacy of the
control group is not a contrast of the controls and the
cases, but a contrast of the controls and the target
population. Using a simulation study of MI, we show
that the selection of controls on factors (LDL) affected by
the exposure of interest (SNP) can bias estimates upward
or downward. The degree of bias and its direction
depended on underlying relationships between the SNP,
LDL, and MI (Figure 1). On the basis of our results, we
caution against the use of poorly characterized control
groups for which the researcher has little information to
assess how well participants represent the target popula-
tion. For instance, the use of “healthy controls” in
genetic association studies has been recently popularized
in genome-wide association studies and it is unknown
how well these control groups represent the underlying
target populations. We believe this deserves greater
consideration because bias was demonstrated even
though the simulated association between the inter-
mediate variable and outcome of interest was modest.
Conclusion
Traditionally included confounders such as smoking and
Rx did not alter effect estimates, even with widely varying
levels of differential and non-differential misclassifica-
tion. However, selecting participants based on covariates
affected by the SNP of interest biased effect estimates in
both directions. Our findings support the need for
careful consideration of how well a study population
represents a target population because bias resulted even
Table 4: Selection bias in the rs1466535-MI association caused by LDL or smoking
Population assessed for selection bias
(100% participation assumed for other subpopulations)
% participating High LDL Low LDL Smoker Non-smoker
Trutha -0.219 -0.219 -0.219 -0.219
95 -0.002 0.002 0.002 -0.002
90 -0.005 0.004 0.004 -0.004
80 -0.012 0.009 0.007 -0.007
70 -0.019 0.014 0.010 -0.008
60 -0.030 0.019 0.014 -0.013
50 -0.049 0.023 0.018 -0.019
40 -0.069 0.028 0.022 -0.023
aModel with 100% participation.
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though the simulated association between rs1466535
and LDL was modest.
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